Solazyme Announces U.S. Commercial Production of Renewable™ Algal Oils at Iowa Facilities

  Solazyme Announces U.S. Commercial Production of Renewable™ Algal Oils at
  Iowa Facilities

Business Wire

SOUTH SAN FRANCISCO, Calif. -- January 30, 2014

Solazyme, Inc. (NASDAQ:SZYM), a Renewable™ oil and bioproducts company,
announced today that commercial operations have commenced at both Archer
Daniels Midland Company (ADM)’s Clinton, Iowa facility, and the downstream
companion facility operated by American Natural Products in Galva, Iowa (ANP).
Highlighting the flexibility of Solazyme’s technology platform, Solazyme, ADM
and ANP have successfully manufactured three distinct and unique Tailored^TM
oil products at the facilities, and products are currently being sold and
distributed in both the U.S. and Brazil. Volumes shipped to Brazil are being
utilized for market development activity in advance of the opening of the
Solazyme Bunge Renewable Oils Moema facility. As stated previously, production
at the ADM and ANP facilities is expected to ramp to a nameplate capacity of
20,000 MT/yr within 12-18 months, with targeted potential expansion to 100,000
MT/yr in subsequent years.

“This is a critical milestone for Solazyme’s large scale commercial
manufacturing capabilities. The Solazyme, ADM and ANP teams have done an
excellent job bringing up commercial operations at the Iowa facilities with
Solazyme’s Tailored^TM oil production technology. We have already successfully
produced three Tailored^TM oil products at scale and have begun selling these
products into the North American marketplace,” said Jonathan Wolfson, CEO
Solazyme. “Consistent with our stated plans, we are focused initially on
ensuring consistent and reliable operations as we build customer trust. While
we acknowledge that it is still early days, we look forward to the opportunity
to expand our production volume and the slate of oil products available.”

Truckloads of product are now shipping from the Iowa operations for use in
applications including lubricants, metalworking and home and personal care.
These shipments are being made pursuant to multiple supply agreements as well
as spot purchases, and include reorders.

In the high-performance lubricants and metalworking fluids industries,
Solazyme’s Renewable™ Tailored™ algal oils help to provide outstanding
performance and a sustainable solution with better lubrication, surface
tension and viscosity index, plus enhanced stability at elevated temperature,
pressure and speed. In home and personal care, Solazyme’s Tailored™ algal oils
offer better performance and a more sustainable alternative to existing oils.

About Solazyme, Inc.

Solazyme, Inc. (SZYM) is a Renewable™ oil and bioproducts company that
transforms a range of low-cost plant-based sugars into high-value oils.
Headquartered in South San Francisco, Solazyme's Renewable™ products can
replace or enhance oils derived from the world's three existing sources –
petroleum, plants and animal fats. Initially, Solazyme is focused on
commercializing its products into three target markets: (1) fuels and
chemicals, (2) nutrition and (3) skin and personal care.

Tailored^TM, Renewable^TM, Solazyme®, and the Solazyme logo are trademarks of
Solazyme, Inc.

About ADM

For more than a century, the people of Archer Daniels Midland Company (NYSE:
ADM) have transformed crops into products that serve vital needs. Today,
30,000 ADM employees around the globe convert oilseeds, corn, wheat and cocoa
into products for food, animal feed, industrial and energy uses. With more
than 265 processing plants, 460 crop procurement facilities, and the world’s
premier crop transportation network, ADM helps connect the harvest to the home
in more than 140 countries. For more information about ADM and its products,
visit www.adm.com.

Forward Looking Statements

This press release contains certain forward-looking statements about Solazyme,
including statements that involve risks and uncertainties concerning: the
scheduled completion of manufacturing facilities; the capacity and
expandability of its manufacturing facilities and the timetable for reaching
capacity; the uses of its products; the attributes and future performance of
its products; production volume and number of available products. When used in
this press release, the words “will”, “expects”, “intends” and other similar
expressions and any other statements that are not historical facts are
intended to identify those assertions as forward-looking statements. Any such
statement may be influenced by a variety of factors, many of which are beyond
the control of Solazyme, that could cause actual outcomes and results to be
materially different from those projected, described, expressed or implied in
this press release due to a number of risks and uncertainties. Potential risks
and uncertainties include, among others: Solazyme’s limited operating history;
its limited history in commercializing products; implementation risk in
deploying new technologies; implementation risk in deploying its technology at
ADM’s Clinton facility; its limited experience in retrofitting, constructing
and operating commercial manufacturing facilities; market acceptance of its
products; meeting market demand; production delays related to the ramping up
and ongoing operation and optimization of production facilities; the
performance of products; its access to adequate supply of feedstock on
favorable terms; its ability to enter into and maintain strategic
collaborations; its ability to obtain requisite regulatory approvals or
permits; and its access, on favorable terms, to any required financing.
Accordingly, no assurances can be given that any of the events anticipated by
the forward-looking statements will transpire or occur, or if any of them do
so, what impact they will have on the results of operations or financial
condition of Solazyme.

In addition, please refer to the documents that Solazyme, Inc. files with the
Securities and Exchange Commission, including its Quarterly Reports on Form
10-Q for a discussion of these and other risks. You are cautioned not to place
undue reliance on forward-looking statements, which speak only as of the date
of this press release. Solazyme is not under any duty to update any of the
information in this press release.

Contact:

Solazyme, Inc.
Genet Garamendi, 650-780-4777
VP Corporate Communications
Press@Solazyme.com
or
Brainerd Communicators, Inc.
Jeff Majtyka, 212-986-6667
majtyka@braincomm.com
Brad Edwards, 212-986-6667
edwards@braincomm.com
 
Press spacebar to pause and continue. Press esc to stop.